TuHURA Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
HURA Nasdaq 2836 www.tuhurabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for TuHURA Biosciences, Inc.

HURA: Focus on the Delta Opioid Receptor - Dec 22nd, 2025 12:15 am
TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone - Dec 15th, 2025 5:50 am
TuHURA Biosciences Provides Corporate Update Following Recent Financing - Dec 11th, 2025 5:30 am
TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering - Dec 9th, 2025 7:49 am
TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition - Dec 8th, 2025 5:50 am
HURA: Third Quarter Results - Nov 17th, 2025 9:05 am
TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - Nov 14th, 2025 5:00 am
TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition - Nov 3rd, 2025 7:01 am
HURA: IFx-2.0 Phase III Begins - Aug 21st, 2025 3:41 am
TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference - Aug 20th, 2025 6:00 am
TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - Aug 14th, 2025 2:15 pm
TuHURA Biosciences, Inc.'s (NASDAQ:HURA) last week's 11% decline must have disappointed retail investors who have a significant stake - Aug 11th, 2025 4:11 am
TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - Jul 1st, 2025 6:50 am
TuHURA Biosciences Completes Acquisition of Kineta - Jun 30th, 2025 6:50 am
TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma - Jun 24th, 2025 6:00 am
TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals - Jun 23rd, 2025 3:00 pm
FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma - Jun 9th, 2025 6:00 am
TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy - Jun 3rd, 2025 7:58 am
TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting - Jun 2nd, 2025 6:03 am
HURA: First Quarter 2025 Results - May 19th, 2025 3:59 am